J&J's Tremfya Shows Positive Results in Axial Psoriatic Arthritis Study
Johnson & Johnson reported that Tremfya met its primary and major secondary endpoints in a Phase 4 study for axial psoriatic arthritis. At week 24, it improved disease activity scores and reduced MRI-confirmed inflammation. The safety profile was consistent with previous data, and detailed results will be presented at a future congress.
The STAR trial enrolled 411 biologic-naïve adults with active psoriatic arthritis and MRI-confirmed axial inflammation, making it the first dedicated study to use objective imaging to verify axial involvement. The randomized, double-blind, placebo-controlled design included a 24-week placebo-controlled phase followed by 24 weeks of active treatment.
Tremfya's safety profile in the study matched its established record in psoriatic arthritis, with no new safety signals reported. The drug previously received FDA label expansion covering inhibition of structural joint damage progression in adults with active PsA. Full efficacy and safety data, including MRI findings, will be released at an upcoming scientific congress.
This development could affect axial PsA patients who have historically had limited targeted options for spinal symptoms. If confirmed at the upcoming congress, the MRI-based evidence may strengthen clinical confidence in IL-23 inhibition for this condition, potentially influencing treatment guidelines and prescribing decisions. Patients could benefit from a therapy addressing both symptoms and objective inflammation, though broader impact will depend on comparative effectiveness against existing treatments and eventual payer coverage decisions.